Eurofins Scientific SE has signed a definitive agreement to acquire Lancaster Laboratories, Inc. from Thermo Fisher Scientific, Inc. for approximately US$200m, subject to post-closing adjustments.
With approximately 1,100 employees in the USA and Ireland, Lancaster is a leading provider of pharmaceutical product testing services and cGMP Quality Control (QC) in North America. In addition, it operates one of the leading environmental testing laboratories in the USA.
With this bolt on acquisition, the Eurofins Group becomes the global leader in this very stable and recurring business and significantly enlarges its North American footprint. It is a further expression of Eurofins’ commitment to serve the pharmaceutical and biotechnology industries with laboratory services of the highest quality and reliability.
Completion of the transaction is expected in the next 2-3 months and is subject to applicable regulatory approvals and customary closing conditions. Implied EV/EBITDA multiple is in-line with levels previously communicated for transactions of this size and Eurofins’ value-creation objectives. Given that Lancaster is already a single-site laboratory in the USA, no site consolidations or restructuring costs are foreseen as a result of this acquisition. Based on Lancaster’s historic profitability and budget for 2011, the transaction should be immediately margin and EPS accretive for Eurofins.